FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385286657> ?p ?o ?g. }

• W4385286657 endingPage "410" @default.
• W4385286657 startingPage "405" @default.
• W4385286657 abstract "The aim of the study was to observe the safety and efficacy of anlotinib (ANL) alone or combined with S-1 in the first-line treatment of advanced hepatocellular carcinoma (HCC).Fifty-four patients with untreated advanced HCC who could not be resected were randomly divided into the ANL group (n = 27) and ANL+S-1 group (n = 27). The ANL group was given 10 mg ANL orally once a day for 14 consecutive days, stopped for 1 week, and repeated every 21 days. The ANL+S-1 group was given 10 mg ANL once a day orally and 40 mg S-1 twice a day orally for 14 consecutive days, stopped for 1 week, repeated every 21 days. All patients were treated until the disease progressed or toxicity became unacceptable. For patients who could not tolerate adverse reactions, the ANL dose should be reduced to 8 mg per day. CT or MRI was reviewed every 6 weeks to evaluate the efficacy.A total of 44 patients were included in the results analysis, including 22 patients in the ANL group and 22 patients in the ANL+S-1 group. In the ANL group, the objective response rate (ORR) was 4.5% (1/22), the disease control rate (DCR) was 77.3% (17/22), the median progression-free survival (PFS) was 4.2 months (95% CI: 3.6-6.0) and the median overall survival (mOS) was 7.0 months (95% CI: 6.3-9.0). In the ANL+S-1 group, the ORR was 18.2% (4/22), the DCR was 59.1% (13/22), the median PFS was 4.0 months (95% CI: 3.6-5.4) and the mOS was 6.0 months (95% CI: 5.5-7.4). There was no significant difference in ORR (p = 0.345) or DCR (p = 0.195) between the two groups. Adverse reactions were mainly hypertension, anorexia, fatigue, liver transaminase heightened and hand and foot skin reaction.ANL monotherapy was effective in the treatment of advanced HCC, and adverse reactions have been able to tolerated." @default.
• W4385286657 created "2023-07-27" @default.
• W4385286657 creator A5002511876 @default.
• W4385286657 creator A5020460652 @default.
• W4385286657 creator A5025346098 @default.
• W4385286657 creator A5040143770 @default.
• W4385286657 creator A5074783604 @default.
• W4385286657 date "2023-07-26" @default.
• W4385286657 modified "2023-10-18" @default.
• W4385286657 title "Effectiveness and safety of anlotinib with or without S-1 in the treatment of patients with advanced hepatocellular carcinoma in a Chinese population: a prospective, phase 2 study" @default.
• W4385286657 cites W1506777089 @default.
• W4385286657 cites W1971837077 @default.
• W4385286657 cites W1994193851 @default.
• W4385286657 cites W2068666196 @default.
• W4385286657 cites W2084590325 @default.
• W4385286657 cites W2147172608 @default.
• W4385286657 cites W2480981995 @default.
• W4385286657 cites W2588177383 @default.
• W4385286657 cites W2771874080 @default.
• W4385286657 cites W2887102596 @default.
• W4385286657 cites W2887865671 @default.
• W4385286657 cites W2890100090 @default.
• W4385286657 cites W2914358135 @default.
• W4385286657 cites W2922410525 @default.
• W4385286657 cites W2952461028 @default.
• W4385286657 cites W2997301311 @default.
• W4385286657 cites W3032195772 @default.
• W4385286657 cites W3043030551 @default.
• W4385286657 cites W3112457091 @default.
• W4385286657 cites W3119208567 @default.
• W4385286657 cites W3133752429 @default.
• W4385286657 cites W3194740391 @default.
• W4385286657 cites W4280593220 @default.
• W4385286657 cites W4306804350 @default.
• W4385286657 doi "https://doi.org/10.2478/raon-2023-0036" @default.
• W4385286657 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37494583" @default.
• W4385286657 hasPublicationYear "2023" @default.
• W4385286657 type Work @default.
• W4385286657 citedByCount "0" @default.
• W4385286657 crossrefType "journal-article" @default.
• W4385286657 hasAuthorship W4385286657A5002511876 @default.
• W4385286657 hasAuthorship W4385286657A5020460652 @default.
• W4385286657 hasAuthorship W4385286657A5025346098 @default.
• W4385286657 hasAuthorship W4385286657A5040143770 @default.
• W4385286657 hasAuthorship W4385286657A5074783604 @default.
• W4385286657 hasBestOaLocation W43852866571 @default.
• W4385286657 hasConcept C126322002 @default.
• W4385286657 hasConcept C141071460 @default.
• W4385286657 hasConcept C188816634 @default.
• W4385286657 hasConcept C197934379 @default.
• W4385286657 hasConcept C2778019345 @default.
• W4385286657 hasConcept C2908647359 @default.
• W4385286657 hasConcept C29730261 @default.
• W4385286657 hasConcept C71924100 @default.
• W4385286657 hasConcept C90924648 @default.
• W4385286657 hasConcept C99454951 @default.
• W4385286657 hasConceptScore W4385286657C126322002 @default.
• W4385286657 hasConceptScore W4385286657C141071460 @default.
• W4385286657 hasConceptScore W4385286657C188816634 @default.
• W4385286657 hasConceptScore W4385286657C197934379 @default.
• W4385286657 hasConceptScore W4385286657C2778019345 @default.
• W4385286657 hasConceptScore W4385286657C2908647359 @default.
• W4385286657 hasConceptScore W4385286657C29730261 @default.
• W4385286657 hasConceptScore W4385286657C71924100 @default.
• W4385286657 hasConceptScore W4385286657C90924648 @default.
• W4385286657 hasConceptScore W4385286657C99454951 @default.
• W4385286657 hasIssue "3" @default.
• W4385286657 hasLocation W43852866571 @default.
• W4385286657 hasLocation W43852866572 @default.
• W4385286657 hasLocation W43852866573 @default.
• W4385286657 hasOpenAccess W4385286657 @default.
• W4385286657 hasPrimaryLocation W43852866571 @default.
• W4385286657 hasRelatedWork W113810927 @default.
• W4385286657 hasRelatedWork W1586374228 @default.
• W4385286657 hasRelatedWork W2003938723 @default.
• W4385286657 hasRelatedWork W2047967234 @default.
• W4385286657 hasRelatedWork W2118496982 @default.
• W4385286657 hasRelatedWork W2364998975 @default.
• W4385286657 hasRelatedWork W2369162477 @default.
• W4385286657 hasRelatedWork W2439875401 @default.
• W4385286657 hasRelatedWork W4238867864 @default.
• W4385286657 hasRelatedWork W2525756941 @default.
• W4385286657 hasVolume "57" @default.
• W4385286657 isParatext "false" @default.
• W4385286657 isRetracted "false" @default.
• W4385286657 workType "article" @default.